Evidence map›Paper›PMID 41290645›Full record

ArticleNature communications2025

Intravaginal delivery of mRNA-encoded antibodies with enhanced breadth and potency for SHIV/HIV protection.

Jae Yeon Joo, Peng Xiao, Susan P John, Daryll Vanover, Hannah E Peck, Loren E Sasser, Deepanwita Bose, Younghun Jung, Jaehyeon Hwang, Chiara Zurla and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jae Yeon JooWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA.
Peng XiaoNew Iberia Research Center, University of Louisiana Lafayette, Lafayette, LA, USA.ORCID http://orcid.org/0000-0002-5308-8400
Susan P JohnNew Iberia Research Center, University of Louisiana Lafayette, Lafayette, LA, USA.ORCID http://orcid.org/0000-0002-3077-5523
Daryll VanoverWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-8744-5923
Hannah E PeckWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA.
Loren E SasserWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0003-3348-9933
Deepanwita BoseNew Iberia Research Center, University of Louisiana Lafayette, Lafayette, LA, USA.ORCID http://orcid.org/0000-0003-4164-6556
Younghun JungWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA.
Jaehyeon HwangWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-3855-4098
Chiara ZurlaWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA.
Francois VillingerNew Iberia Research Center, University of Louisiana Lafayette, Lafayette, LA, USA. francois.villinger@louisiana.edu.ORCID http://orcid.org/0000-0002-7790-2008
Philip J SantangeloWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA. philip.j.santangelo@emory.edu.ORCID http://orcid.org/0000-0001-7352-0339

Funding

Whole body to single cell analysis of the HIV reservoirR01AI139288 · NIAID · UNIVERSITY OF LOUISIANA AT LAFAYETTE · PI SANTANGELO, PHILIP J, VILLINGER, FRANCOIS J · 2018 to 2022
$3.7M
Durable Vaginal Protection from HIV via mRNA expression of BNABSR01AI155007 · NIAID · GEORGIA INSTITUTE OF TECHNOLOGY · PI SANTANGELO, PHILIP J, VILLINGER, FRANCOIS J · 2020 to 2025
$3.5M
NIAID NIH HHS R01 AI139288NIAID NIH HHS R01 AI155007U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI139288U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI155007
6 · The paper itself

Abstract

Broadly neutralizing antibodies (bnAbs) prevent HIV infection but face administration and cost challenges. We present single-chain mRNA-encoded bnAbs that improve heavy-light chain assembly and enable three enhancement approaches: co-expression, isotype selection, and engineered nanobodies. We observe enhanced in vitro neutralization through co-expression of PGT121 and VRC07 (targeting V3-glycan and CD4-binding site, respectively) and by replacing IgG constant heavy chain (IgG-C

Indexed as

Antibodies, NeutralizingBroadly Neutralizing AntibodiesHIV AntibodiesHIV InfectionsRNA, MessengerSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusAdministration, IntravaginalAnimalsFemaleHIV-1HumansImmunoglobulin GImmunoglobulin MMacaca mulattaSingle-Chain AntibodiesAntibodies, NeutralizingBroadly Neutralizing AntibodiesHIV AntibodiesImmunoglobulin GImmunoglobulin MRNA, MessengerSingle-Chain Antibodies

Identifiers

PMID41290645
PMCPMC12647688

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.